Literature DB >> 15105064

Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study.

Satu Suhonen1, Maija Haukkamaa, Tell Jakobsson, Ilkka Rauramo.   

Abstract

This 1-year randomized study was carried out at family-planning clinics of two university hospitals to compare the safety and acceptability of a levonorgestrel-releasing intrauterine system (LNG IUS) and oral contraceptives (OCs) in young nulliparous women. The study population consisted of 200 women aged 18-25 years seeking contraception. Ninety-four women entered the LNG IUS group and 99 entered the OC group. Continuation rates, reasons leading to discontinuation, adverse events, menstrual questionnaires, subjective well-being and sexual behavior were evaluated. Nineteen women (20%) in the LNG IUS group discontinued the study during the 1-year observation period, and 27 discontinued (27%) in the OC group. The most common reason (31%) for discontinuation in the IUS group was pain. In the OC group, hormonal side effects were the predominant medical reason for study termination. The safety and acceptability of the LNG IUS for contraception was observed to be as good as with OCs, with a high continuation rate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105064     DOI: 10.1016/j.contraception.2003.11.008

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  32 in total

1.  Failed IUD insertions in community practice: an under-recognized problem?

Authors:  Amna I Dermish; David K Turok; Janet C Jacobson; Marie E S Flores; Molly McFadden; Kathy Burke
Journal:  Contraception       Date:  2012-09-11       Impact factor: 3.375

2.  Immediate post-abortion insertion of intrauterine contraceptives (IUC) in a diverse urban population.

Authors:  DeShawn Taylor; Shannon Connolly; Sue Ann Ingles; Carey Watson; Penina Segall-Gutierrez
Journal:  J Immigr Minor Health       Date:  2014-06

3.  Continuation of reversible contraception in teenagers and young women.

Authors:  Jessica R Rosenstock; Jeffrey F Peipert; Tessa Madden; Qiuhong Zhao; Gina M Secura
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

4.  The levonorgestrel-releasing intrauterine system is associated with delayed endocervical clearance of Chlamydia trachomatis without alterations in vaginal microbiota.

Authors:  Emma R Liechty; Ingrid L Bergin; Christine M Bassis; Daniel Chai; William LeBar; Vincent B Young; Jason D Bell
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

5.  Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction.

Authors:  Justin T Diedrich; Sanyukta Desai; Qiuhong Zhao; Gina Secura; Tessa Madden; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2014-07-18       Impact factor: 8.661

6.  Contraceptive sex acceptability: a commentary, synopsis and agenda for future research.

Authors:  Jenny A Higgins; Anne R Davis
Journal:  Contraception       Date:  2014-03-11       Impact factor: 3.375

Review 7.  The safety of intrauterine devices among young women: a systematic review.

Authors:  Tara C Jatlaoui; Halley E M Riley; Kathryn M Curtis
Journal:  Contraception       Date:  2016-10-19       Impact factor: 3.375

8.  Weight change at 12 months in users of three progestin-only contraceptive methods.

Authors:  Zevidah Vickery; Tessa Madden; Qiuhong Zhao; Gina M Secura; Jenifer E Allsworth; Jeffrey F Peipert
Journal:  Contraception       Date:  2013-03-18       Impact factor: 3.375

9.  Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use.

Authors:  Manuela Mejia; Colleen McNicholas; Tessa Madden; Jeffrey F Peipert
Journal:  Contraception       Date:  2016-06-27       Impact factor: 3.375

10.  Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.

Authors:  Chandra Kailasam; David Cahill
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.